Knowledge Hub

Global Schizophrenia Market Opportunities, Trends, Size, Drivers, Strategies, ProductsClinical Trials Review, H2, 2016

Press Release   •   Nov 11, 2016 05:38 EST

GlobalData's clinical trial report, Schizophrenia Global Clinical Trials Review, H2, 2016" provides an overview of Schizophrenia clinical trials scenario. This report provides top line data relating to the clinical trials on Schizophrenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

View Report At :


- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

Download Sample copy of this Report at :

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12

Top Five Countries Contributing to Clinical Trials in Central and South America 13

Clinical Trials by G7 Countries: Proportion of Schizophrenia to Central Nervous System Clinical Trials 14

Clinical Trials by Phase in G7 Countries 15

Clinical Trials in G7 Countries by Trial Status 16

Clinical Trials by E7 Countries: Proportion of Schizophrenia to Central Nervous System Clinical Trials 17

Clinical Trials by Phase in E7 Countries 18

Clinical Trials in E7 Countries by Trial Status 19

Clinical Trials by Phase 20

In Progress Trials by Phase 21

Clinical Trials by Trial Status 22

Clinical Trials by End Point Status 23

Subjects Recruited Over a Period of Time 24

Clinical Trials by Sponsor Type 25

Prominent Sponsors 26

Top Companies Participating in Schizophrenia Therapeutics Clinical Trials 27

Prominent Drugs 29

Latest Clinical Trials News on Schizophrenia 30

Oct 03, 2016: Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia 30

Sep 28, 2016: Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study 302) 30

Sep 26, 2016: Minerva Neurosciences Provides Update on MIN-101 Clinical Program 32

Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress 32

Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate 33

Aug 08, 2016: Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda (lurasidone HCl) in the Treatment of Schizophrenia 34

Aug 05, 2016: Allergan and Richter Provide Update on Cariprazine Program 34

Aug 01, 2016: Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia 35

Clinical Trial Profile Snapshots 37

Appendix 1314

Abbreviations 1314

Definitions 1314

Research Methodology 1315

Secondary Research 1315

About GlobalData 1316

Contact Us 1316

Disclaimer 1316 is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.